Get Short URL
NOVOSIBIRSK (Sputnik) – Viral vector and mRNA vaccines, including Russian Sputnik V, provide adequate protection against the new Delta strain of the coronavirus, Sergey Netesov, chief of the laboratory at Novosibirsk State University and corresponding member of the Russian Academy of Sciences (RAS) Sputnik.
“According to data from the UK, US and other countries, mRNA and vector vaccines, including our Sputnik V, protect against it [the Delta variant], albeit to a lesser extent, but they do protect against it. They provided 95% protection against the initial load and now they offer 90% protection against the ‘delta’ variant,” Netesov said.
He added that the vaccines already developed should be used because they are quite effective.
In late June, Vladimir Gushchin, the head of the population variability mechanisms lab at the Gamaleya research center that developed the Sputnik V vaccine, said the Russian injections provide nearly 100 percent protection against severe and fatal cases of COVID-19 caused by the Delta strain.
Russia became the first country in the world to register a vaccine against the coronavirus, called Sputnik V, in August 2020.
Sputnik V, also known as Gam-COVID-Vac, uses two different engineered adenoviruses (rAd26 and rAd5 for the first and second dose, respectively) to generate the genetic code for the coronavirus spike protein (SARS-CoV-2) in human cells. Adenoviruses usually cause only mild disease in humans, and by opting for two different delivery mechanisms, rather than using just one engineered adenovirus like the Oxford-AstraZeneca and Johnson & Johnson vaccines, the Russian developers wanted to increase the vaccine’s efficacy.
Sputnik V was also the first developer to partner and partner for vaccine cocktails, an approach that Daniel Altmann says. @ Daltmann10, an immunologist at ICL, cited in @Nature, opens “a brave new world of vaccinology to be explored.”
— Sputnik V (@sputnik vaccine) May 21, 2021
According to an interim analysis of a trial published in the medical journal The Lancet, the Sputnik V vaccine has an efficacy of 91.6 percent. Meanwhile, the Gamaleya National Research Center of Epidemiology and Microbiology, which developed Sputnik V, and the Russian Direct Investment Fund (RDIF) reported that Sputnik V has an efficacy of 97.6 percent.
Unlike both the Oxford-AstraZeneca and Johnson & Johnson vaccines, there have been no reports of rare blood clotting disorders in people vaccinated with Sputnik V by Russian health authorities or from more than 60 countries now using Sputnik V.